High-Throughput Screening of Low Molecular Weight NS3-NS4A Protease Inhibitors Using a Fluorescence Resonance Energy Transfer Substrate

Hepatitis C virus (HCV) NS3-NS4A protease is an attractive target for anti-HCV agents because of its important role in replication. An optimized fluorescence resonance energy transfer (FRET) substrate for NS3-NS4A protease, based on the sequence of the NS5A-5B cleavage site, was designed and synthesized. High-throughput screening of in-house compound libraries was performed using a FRET substrate FS10 (MOCAc-DKIVPC-SMSYK-Dnp) and MBP-NS3-NS4A fusion protein. Several hit compounds were found, including YZ-9577 (2-oxido-1,2,5-oxadiazole-3,4-diyl) bis (phenylmethanone) with potent inhibitory activity (IC50=1.6 μM) and good selectivity against other human serine proteases.

[1]  K. Shimotohno,et al.  Bacterial expression and analysis of cleavage activity of HCV serine proteinase using recombinant and synthetic substrate. , 1995, Biochemical and biophysical research communications.

[2]  K. Shimotohno,et al.  Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. , 1997, Biochemical and biophysical research communications.

[3]  R. Francesco,et al.  Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins , 1994, Journal of virology.

[4]  M. Houghton,et al.  Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease , 1991, Hepatology.

[5]  A. Urbani,et al.  A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. , 1996, Analytical biochemistry.

[6]  A. Urbani,et al.  Activity of purified hepatitis C virus protease NS3 on peptide substrates , 1996, Journal of virology.

[7]  N. Kato,et al.  Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus , 1993, Journal of virology.

[8]  H. Okayama,et al.  Structure and organization of the hepatitis C virus genome isolated from human carriers , 1991, Journal of virology.

[9]  K. Shimotohno,et al.  Novel Hepatitis C virus Protease Inhibitors: 2,4,6-Trihydroxy,3-Nitro-Benzamide Derivatives , 1997 .

[10]  C. Rice,et al.  Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites , 1993, Journal of virology.

[11]  C. Decicco,et al.  Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. , 2003, Bioorganic & medicinal chemistry letters.

[12]  X. Forns,et al.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. , 2004, Gastroenterology.

[13]  Y. Masuho,et al.  Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease , 1996, Journal of virology.

[14]  G. Fields,et al.  Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). , 1994, The Journal of biological chemistry.

[15]  B. Dunn,et al.  A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. , 1995, Analytical biochemistry.

[16]  K. Shimotohno,et al.  A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. , 1999, Journal of virological methods.

[17]  K. Shimotohno,et al.  Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. , 1996, Antiviral research.

[18]  J. Pichardo,et al.  Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum. , 1999, Bioorganic & medicinal chemistry letters.

[19]  P. Barr,et al.  Genetic organization and diversity of the hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G Murphy,et al.  A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.

[21]  K. Shimotohno,et al.  Non‐peptide inhibitors of HCV serine proteinase , 1998, FEBS letters.

[22]  Todd C Appleby,et al.  Hepatitis C Virus Therapies: Current Treatments, Targets and Future Perspectives , 2003, Antiviral chemistry & chemotherapy.

[23]  B. Douty,et al.  Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[24]  Steven R. LaPlante,et al.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.

[25]  K. Shimotohno,et al.  Expression of a hepatitis C virus NS3 protease-NS4A fusion protein in Escherichia coli. , 1998, Biochemical and biophysical research communications.

[26]  Gary T. Wang,et al.  Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. , 1990, Science.

[27]  C. Rice,et al.  The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Handa,et al.  Design and Synthesis of a Quenched Fluorogenic Peptide Substrate for Human Cytomegalovirus Proteinase , 1995 .

[29]  Martin Poirier,et al.  Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position. , 2004, Journal of medicinal chemistry.

[30]  Robert B. Johnson,et al.  Development of a Continuous Fluorescence Assay for Rhinovirus 14 3C Protease Using Synthetic Peptides , 1997 .

[31]  R. Bartenschlager,et al.  Kinetic and structural analyses of hepatitis C virus polyprotein processing , 1994, Journal of virology.

[32]  J. Pawlotsky.  The nature of interferon-alpha resistance in hepatitis C virus infection. , 2003, Current opinion in infectious diseases.

[33]  T. Sugimura,et al.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Giovanni Migliaccio,et al.  Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. , 2003, Antiviral research.